GILD  Gilead Sciences Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

93.41B

Vuru Grade

92.50/100

Current Price

$70.90
-0.67 (-0.94%)

Growth Price

$163.94
Undervalued by 131.22%

Stability Price

$51.35
Overvalued by 27.58%

Company Metrics

  • P/E 6.56
  • P/S 2.99
  • P/B 5.61
  • EPS 10.81
  • Cash ROIC 49.59%
  • Cash Ratio 1.48
  • Dividend 1.88 / 2.61%
  • Avg. Vol. 9.77M
  • Shares 1.52B
  • Market Cap. 93.41B

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Is Gilead Sciences (GILD) a Great Stock for Value Investors?
Yahoo Finance - 13 hours ago
We should also point out that Gilead Sciences has a forward PE ratio (price relative to this year's earnings) of 6.90, which is roughly in line with the current level.
Needham Divided On Two Biotech Players: Gilead Sciences, Inc. (GILD), ACADIA ... - Smarter Analyst
Why Gilead Sciences, Inc (NASDAQ:GILD) HCV Franchise Is Completely Worthless! - BNL Finance (press release) (registration) (blog)
Company Update (NASDAQ:GILD): Gilead Sciences, Inc. Announces EMA Validation ...
Smarter Analyst - 15 hours ago
Gilead Sciences, Inc. (NASDAQ:GILD) announced that the company's Marketing Authorization Application (MAA) for the investigational, once-daily, single tablet regimen of sofosbuvir 400 mg, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for the ...
Georgia Bennicas Dba Bennicas & Associates Buys Kellogg Co, Gilead Sciences ...
Nasdaq - 10 hours ago
Georgia Bennicas Dba Bennicas & Associates initiated holdings in Gilead Sciences Inc. The purchase prices were between $71.61 and $78.47, with an estimated average price of $74.33.
Gilead Sciences Inc.'s Biggest Failure in 2016
Motley Fool - Jan 5, 2017
If you've been following this stock for any length of time, you're probably painfully aware that Gilead's hep C franchise sank like a stone last year.
Gilead Sciences Must Answer to Investors After a Disappointing 2016 - Nasdaq
Gilead Sciences Inc.: Why GILD Stock is Worth Owning - Income Investors
Gilead Sciences, Inc.: Is It Time to Consider GILD Stock?
Income Investors - 22 hours ago
Gilead Sciences, Inc. (NASDAQ:GILD) stock is down over 25% over the past year. Is now the time to consider this stock?
Dreman Value Management L L C Reduces Stake in Gilead Sciences Inc. (GILD) - Sports Perspectives
Gilead Sciences Inc. (NASDAQ:GILD) Earns Average Broker Rating Of Outperform - The Independent Republic
Why Gilead Is Undervalued
Seeking Alpha - 8 hours ago
DCF analysis with inputs of lowest analyst estimates or historical averages reveal Gilead is still undervalued based on perpetuity growth method (2% rate) by around 40%.
Will 2017 Be Gilead Sciences Inc.'s Worst Year Yet?
Motley Fool - Dec 25, 2016
It's been a rotten year for Gilead Sciences (NASDAQ:GILD) shareholders. The biotech stock is down over 25% in 2016. Sales for hepatitis C virus (HCV) drugs Harvoni and Sovaldi are dropping like a brick.
what are Analysts report about: Gilead Sciences Inc. (NASDAQ:GILD) - News Oracle
Gilead Sciences, Inc. (NASDAQ:GILD) Rises Over Recent Vemlidy Approval - Smаrt Stоck Nеws
Forget Gilead Sciences Inc.: These 2 Stocks Doubled Last Year
Fox Business - Jan 2, 2017
Long-term holders of Gilead Sciences (NASDAQ: GILD) enjoyed some market-thumping gains in years past, but concern over sagging hepatitis-C antiviral sales caused the stock to slide about 26.5% in 2016.
Agree To Buy Gilead Sciences At $55, Earn 4.4% Using Options
Nasdaq - Jan 17, 2017
Investors eyeing a purchase of Gilead Sciences, Inc. (Symbol: GILD) stock, but cautious about paying the going market price of $72.03/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Cure Your Portfolio With Gilead
Seeking Alpha - Jan 19, 2017
While almost no company was left unscathed, Gilead Sciences was one of the hardest hit companies in the sector. Gilead commenced the year a little over $100 a share and closed the year around $72 a share.